Maureen Dubreuil, MD, MSc.

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Dubreuil is a rheumatologist in Boston, specializing in spondyloarthritis. She works within the Rheumatology section at Chobanian and Avedisian School of Medicine, where her research focuses on comorbidities and pharmacoepidemiology of spondyloarthritis. Dr. Dubreuil's research has been funded by numerous competitive grants from funders including the NIH, private foundations and industry. Some highlights of Dr. Dubreuil's work includes:
1. Discovery of two key protective effects of TNF inhibitors against fractures and cardiovascular events in spondyloarthritis
2. Finding that a common nonsteroidal anti-inflammatory drug is associated with 3 times the risk of heart attack among people with spondyloarthritis
3. Development of the first North American guidelines for referral of adults at increased risk of having spondyloarthritis to a rheumatologist

In addition to her research, Dr. Dubreuil is a member of the leading international organizations for spondyloarthritis research. She serves on the Executive Committee of the Board of Directors for the Spondyloarthritis Research and Treatment Network, and on the Medical Advisory Board for the Spondylitis Association of America. She is a site investigator for the international CLASSIC study in spondyloarthritis. Dr. Dubreuil is the Director of Research Training for the Rheumatology Fellowship program at Boston Medical Center.

Dr. Dubreuil cares for people with rheumatic conditions at Boston Medical Center and the VA Boston Healthcare System. Dr. Dubreuil's patients say the following about her:
"Dr. Dubreuil is a very caring and knowledgeable doctor and it's always a pleasure to be seen by her."
"I am very satisfied with the care I have received. My provider and the support staff is very professional, caring and concerned. I would recommend to anyone."
"Dr. Dubreuil is a gem and I feel so lucky to have her!"
A survey of 40 patients who received care by Dr. Dubreuil in 2024-2025 found that 100% would recommend her!

Publications

  • Published 9/15/2026

    Bittar M, Chalian M, Horbal N, Caplan L, Dubreuil M, Pezeshk P, Stovall R, Kung JY, Gensler LS, Deodhar A, Lambert RGW, Maksymowych WP. What Defines an MRI Considered Indicative of Axial Spondyloarthritis in the Sacroiliac Joints: A Systematic Literature Review. J Rheumatol. 2026 Sep 15. PMID: 42744402.

    Read at: PubMed

  • Published 9/1/2026

    Dubreuil M, Danve A, Liew JW, Alexander SA, Afinogenova Y, Bittar M, Fraenkel L, Grimshaw A, Kumthekar A, LaValley MP, Magrey MN, Majithia V, Merjanah S, Norton H, Walsh JA, Deodhar A. Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist. ACR Open Rheumatol. 2026 Sep; 8(9):e90129. PMID: 42689760.

    Read at: PubMed

  • Published 8/7/2026

    Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Healy P, Lambert J, Mørup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 07. PMID: 42386286.

    Read at: PubMed

  • Published 5/13/2026

    Navarro-Compán V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13; 12(2). PMID: 42128532.

    Read at: PubMed

  • Published 12/1/2025

    Choufani M, Ghusn W, Dubreuil M, Ermann J. Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region. J Rheumatol. 2025 Dec 01; 52(12):1245-1253. PMID: 40089303.

    Read at: PubMed